RNAi Pivot Opportunity Sarepta’s shift to Arrowhead-sourced RNAi assets with early biomarker data creates a doorway for specialized development partnerships, including biomarker assay development, translational analytics, and regulatory support through Phase I/II.

Biomarker Analytics The emphasis on biomarker data and long-term safety signals signals demand for advanced data platforms, real-world evidence programs, registries, and pharmacovigilance services to strengthen clinical filings and market access.

Competitive Positioning With Regenxbio and Solid Biosciences active in Duchenne programs, there is an opportunity to assist in competitive intelligence, go-to-market strategy, and potential manufacturing scale-up or CDMO collaborations to accelerate pipeline execution and differentiation.

Leadership Partnerships The leadership transition to Jorge Bartolome as CEO points to potential for strategic alliance deal origination, licensing negotiations, and joint development frameworks; consider approaching for co-development discussions with aligned risk-sharing terms.

Global Reach Sarepta’s sizable global footprint and commercial revenue create opportunities for multinational clinical trial services, supply chain optimization, regulatory affairs, and patient access initiatives tailored to rare neuromuscular diseases across regions.